A Phase 2 interventional study of Recombinant human luteinizing hormone (rhLH) and Recombinant follicle-stimulating hormone (rFSH) in Infertility and Ovulation Induction, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Spain. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing lutropin alfa in Infertility — 1 open to participants now, 1 under way, 1 of them phase 3. lutropin alfa · Infertility.
Among the 11 studies testing lutropin alfa in Infertility, this one is the 8th largest by enrollment, is the only one that started in 2008, is one of 3 in phase 2, and was the 3rd registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 11 studies testing lutropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
By country, each count listing its studies:
lutropin alfa: first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 35 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2008.
This study's enrollment of 76 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 90 across the 11 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2008, is one of 6 in phase 2, and was the 11th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
1 of the studies testing lutropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing lutropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
This is a multicentric, open, randomized, comparative trial aimed to assess the influence of recombinant luteinizing hormone (r-LH) supplementation during controlled ovarian stimulation (COS) in advanced reproductive age in terms of improved embryo competence which allows to transfer less embryos to avoid high grade multiple pregnancy without reducing the pregnancy rate.
This study will be carried out by the Grupo de Interés de Salud Embrionaria (GISE) group (part of the Spanish Fertility Society) who uses strict criteria to select the embryos most suitable for successful transference.
OBJECTIVES
Primary objective:
Secondary objectives:
To evaluate the benefit of r-LH supplementation in COS, in terms of:
The study will consist of 2 groups randomized in 1:1 ratio and each subject would be followed up until the confirmation of her pregnancy status. Each subject will be administered gonadotropin releasing hormone (GnRH) agonist subcutaneously daily from previous mid luteal phase to r-hCG administration as a standard practice to achieve down regulation. Each subject will also be administered recombinant follicle stimulating hormone (r-FSH) at a starting dose of 300 IU from S1 up to ovarian stimulation completion (r-hCG day) as a part of standard practice. In addition to the above concurrent therapies, one group will be administered experimental treatment (Luveris®) and the other group (control group) will not be administered any other drug (control treatment) during the stimulation period from stimulation start (S1) up to ovarian stimulation completion or stimulation cancellation respectively. Ovarian stimulation on an average takes 11 days and it is expected that stimulation period will not be extended beyond 15 days. A single injection of r-hCG will be administered intramuscularly or subcutaneously after the last injection of Luveris or r-FSH to achieve final follicular maturation. After, 34-36 hours of administration of r-hCG OPU will be done for oocyte retrieval and embryo transfer (ET) will be conducted within 5 days from OPU. Subjects will also be provided luteal support with natural progesterone and will be followed until delivery or miscarriage. Ultrasound and estradiol (E2) assessment of follicular growth will be conducted at various time points during the stimulation period with or without treatment adjustment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.
Drug: Recombinant human luteinizing hormone (rhLH) · Drug: Recombinant follicle-stimulating hormone (rFSH)
rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.
Drug: Recombinant follicle-stimulating hormone (rFSH)
Also known as: Luveris®, Lutropin alfa
Implantation Rate
Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred.
Time frame: Day 35-42 post ovum pick-up (OPU) (34-38 hours post recombinant human choriogonadotropin day {end of stimulation cycle}[approximately 28 days])
Mean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day
Time frame: r-hCG day (end of stimulation cycle [approximately 28 days])
Mean Number of Oocytes Retrieved
Mean number of oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
Time frame: 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])
Number of Mature Oocytes Retrieved
Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity was evaluated based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage.
Time frame: 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])
Number of Fertilized Oocytes (2 Pronuclei [PN])
Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of two 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.
Time frame: 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])
Number and Quality of Embryos
Embryos were graded according to Spanish Association for the Study of Reproductive Biology (ASEBIR) criteria into different categories: (A) optimal quality with maximum capacity for implantation, (B) good quality with a high capacity for implantation, (C) regular with low possibility of implantation and (D) poor quality with very little possibility of implantation.
Time frame: Day 2-3 post OPU (34-38 hours post r-hCG day {end of stimulation cycle}[approximately 28 days])
Number of Participants With Biochemical Pregnancies
Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy.
Time frame: 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Number of Participants With Clinical Pregnancies
Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
Time frame: 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH)
Time frame: 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Estradiol (E2) Levels on r-hCG Day
Time frame: r-hCG day (end of stimulation cycle [approximately 28 days])
Number of Ovarian Stimulation Days
Ovarian stimulation included from first rFSH injection (S1) until day on which r-hCG was administered (r-hCG day). This period was divided into 2 parts: the first period in which 300 International Unit (IU) rFSH dose was constant and which covered from S1 to Day 4 of stimulation period (S4); the second period in which the rFSH dose could be adjusted depending on the ovarian response and which began on S4 and finished on the day on which the criteria for administration of r-hCG to induce the final follicular maturation were met.
Time frame: S1 up to r-hCG day (end of stimulation cycle [approximately 28 days])
Number of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response
Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.
Time frame: Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Total Number of Births
Total number of births per reporting group was calculated.
Time frame: Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Time frame: Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
Time frame: Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
Time frame: Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
| Milestone | rFSH + rhLH | rFSH |
|---|---|---|
| Started | 40 | 35 |
| Completed | 30 | 31 |
| Not completed | 10 | 4 |
| Withdrew: Withdrawal before r-hcg administration | 6 | 1 |
| Withdrew: Withdrawal between rhcg-ovum pickup(opu) | 1 | 1 |
| Withdrew: Withdrawal between opu - embryo transfer | 3 | 2 |
Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred.
| sacs per embryo | rFSH + rhLH | rFSH |
|---|---|---|
| Implantation Rate | 0.2 ± 0.4 | 0.2 ± 0.3 |
| follicles | rFSH + rhLH | rFSH |
|---|---|---|
| Mean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day | 7.7 ± 4.9 | 8.7 ± 4.0 |
Mean number of oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
| oocytes | rFSH + rhLH | rFSH |
|---|---|---|
| Mean Number of Oocytes Retrieved | 5.9 ± 3.9 | 7.7 ± 4.0 |
Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity was evaluated based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage.
| mature oocytes | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Mature Oocytes Retrieved | 234 | 271 |
Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of two 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.
| 2PN oocytes | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Fertilized Oocytes (2 Pronuclei [PN]) | 128 | 136 |
Embryos were graded according to Spanish Association for the Study of Reproductive Biology (ASEBIR) criteria into different categories: (A) optimal quality with maximum capacity for implantation, (B) good quality with a high capacity for implantation, (C) regular with low possibility of implantation and (D) poor quality with very little possibility of implantation.
| embyros | rFSH + rhLH | rFSH |
|---|---|---|
| A + B (good quality) | 69 | 65 |
| C + D (poor quality) | 56 | 73 |
| Total embryos | 125 | 138 |
Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy.
| participants | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Participants With Biochemical Pregnancies | 11 | 10 |
Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
| participants | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Participants With Clinical Pregnancies | 10 | 10 |
| IU | rFSH + rhLH | rFSH |
|---|---|---|
| Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH) | 2812.2 ± 719.4 | 2970.3 ± 748.2 |
| picogram/milliter (pg/mL) | rFSH + rhLH | rFSH |
|---|---|---|
| Estradiol (E2) Levels on r-hCG Day | 1890.2 ± 1084.4 | 1621 ± 827.8 |
Ovarian stimulation included from first rFSH injection (S1) until day on which r-hCG was administered (r-hCG day). This period was divided into 2 parts: the first period in which 300 International Unit (IU) rFSH dose was constant and which covered from S1 to Day 4 of stimulation period (S4); the second period in which the rFSH dose could be adjusted depending on the ovarian response and which began on S4 and finished on the day on which the criteria for administration of r-hCG to induce the final follicular maturation were met.
| Days | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Ovarian Stimulation Days | 9.7 ± 2.1 | 9.8 ± 1.9 |
Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.
| cycles | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response | 4 | 1 |
Total number of births per reporting group was calculated.
| births | rFSH + rhLH | rFSH |
|---|---|---|
| Total Number of Births | 10 | 9 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
| participants | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 19 | 9 |
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
| participants | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS) | 1 | 0 |
OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.
| cycles | rFSH + rhLH | rFSH |
|---|---|---|
| Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS) | 1 | 0 |
Collected over AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 35-42 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rFSH + rhLH | — | 2/40 (5%) | 17/40 (42.5%) |
| rFSH | — | 1/35 (2.9%) | 8/35 (22.9%) |
| Event | rFSH + rhLH | rFSH |
|---|---|---|
| Trisomy 13Congenital, familial and genetic disorders | 0/40 | 1/35 |
| New born hip dysplasiaMusculoskeletal and connective tissue disorders | 1/40 | 0/35 |
| Cutaneous anginomaSkin and subcutaneous tissue disorders | 1/40 | 0/35 |
| Event | rFSH + rhLH | rFSH |
|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 5/40 | 0/35 |
| Pain at the injection siteGeneral disorders | 5/40 | 0/35 |
| PruritusSkin and subcutaneous tissue disorders | 4/40 | 1/35 |
| HeadacheNervous system disorders | 4/40 | 3/35 |
| HaematomaVascular disorders | 4/40 | 1/35 |
| EcchymosisSkin and subcutaneous tissue disorders | 3/40 | 0/35 |
| Subcutaneous haematomaInjury, poisoning and procedural complications | 2/40 | 2/35 |
| DizzinessNervous system disorders | 1/40 | 2/35 |
| PainGeneral disorders | 1/40 | 2/35 |
| Premature birthPregnancy, puerperium and perinatal conditions | 2/40 | 1/35 |
| Age, Continuous(years) | rFSH + rhLH | rFSH | Total |
|---|---|---|---|
| Mean | 37.2 ± 2.2 | 37.3 ± 1.5 | 37.2 ± 1.9 |
| Sex: Female, Male(Participants) | rFSH + rhLH | rFSH | Total |
|---|---|---|---|
| Female | 40 | 35 | 75 |
| Male | 0 | 0 | 0 |
The record gives a start of Nov 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutropin alfa
Merck KGaA, Darmstadt, Germany →